| 0 (0%) | 09-11 13:38 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.38 | 1-year : | 3.73 |
| Resists | First : | 2.9 | Second : | 3.2 |
| Pivot price | 2.58 |
|||
| Supports | First : | 2.41 | Second : | 2.01 |
| MAs | MA(5) : | 2.53 |
MA(20) : | 2.6  |
| MA(100) : | 3.11 |
MA(250) : | 5.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.4 |
D(3) : | 24.6 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 10 | Low : | 2.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRVO ] has closed below upper band by 45.3%. Bollinger Bands are 79% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.53 - 2.55 | 2.55 - 2.57 |
| Low: | 2.43 - 2.45 | 2.45 - 2.47 |
| Close: | 2.45 - 2.49 | 2.49 - 2.51 |
Fri, 11 Sep 2026
CRVO: Neflamapimod advances toward phase III in DLB, with pivotal data and new programs driving near-term catalysts - TradingView
Fri, 11 Sep 2026
CRVO: Phase III-ready DLB therapy neflamapimod shows strong efficacy and biomarker support - TradingView
Thu, 10 Sep 2026
CervoMed (NASDAQ: CRVO) data accepted for late-breaking dementia conference talk - Stock Titan
Mon, 06 Jul 2026
An opening behind an occlusion: carotico-cavernous fistula presenting as central retinal vein occlusion - Nature
Thu, 18 Jun 2026
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
Thu, 18 Jun 2026
CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 9.6e+006 (%) |
| Held by Institutions | 26.4 (%) |
| Shares Short | 827 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 406.9 % |
| Return on Equity (ttm) | -60.8 % |
| Qtrly Rev. Growth | 331300 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.6 |
| Dividend | 0 |
| Forward Dividend | 962580 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|